High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents
| Autor: | Efstathios Kastritis, Dimitrios Christoulas, Maria Gavriatopoulou, Kim Leitzel, Evangelos Terpos, Konstantinos Anargyrou, Meletios A. Dimopoulos, Vikas Shrivastava, Magdalini Migkou, Peter J. Hamer, Walter P. Carney, Allan Lipton |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Pathology Bone disease Antineoplastic Agents Enzyme-Linked Immunosorbent Assay Kaplan-Meier Estimate Article Bortezomib Internal medicine medicine Advanced disease Biomarkers Tumor Humans In patient Stage (cooking) Multiple myeloma Aged Aged 80 and over Tissue Inhibitor of Metalloproteinase-1 business.industry Hematology Middle Aged medicine.disease Prognosis Boronic Acids Lytic cycle Novel agents Pyrazines Female business Multiple Myeloma medicine.drug |
| Zdroj: | Leukemia research. 34(3) |
| ISSN: | 1873-5835 |
| Popis: | Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage ( p = 0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1–1.006), p = 0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect